GLPwatch
Papers (10389)
Page 148 of 174, ranked by citation count.
- Uncovering the potential molecular mechanism of liraglutide to alleviate the effects of high glucose on myoblasts based on high-throughput transcriptome sequencing technique.
- Functional hydrophilic polystyrene beads with uniformly size and high cross-linking degree facilitated rapid separation of exenatide.
- Discontinuation of Tirzepatide and Semaglutide Prior to Gastric Sleeve Surgery: Clinical Considerations and Guidelines.
- Targeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agonist Therapies.
- Comparative Efficacy and Safety of Different Orforglipron Doses in Patients With Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Network Meta-Analysis.
- CORRECTION: Ozempic v Mounjaro: what is the difference between semaglutide and tirzepatide?
- Tirzepatide is Associated With Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients With Type 2 Diabetes.
- Effectiveness of Telemedicine Prescribing and a Long-Acting Obesity Medication Behavioral Program: A 24-Week Single-Arm Study.
- Tirzepatide (Zepbound) for obstructive sleep apnea.
- Comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 trials".
- Multiple analysis based on dual-mode anion-exchange chromatography strategy reveals significant impact of charge heterogeneity on structure and function of dulaglutide.
- Semaglutide (Ozempic) for weight loss.
- Linking GLP-1 activation with steroidogenesis, redox, endoplasmic reticulum stress, mitophagy, and the apoptotic regulatory network unlocks the emerging impacts of semaglutide on 5-fluorouracil-induced testicular toxicity.
- A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial.
- Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis.
- Oral delivery of peptides and proteins: pharmacokinetic boundaries, negative selection, and route triage.
- High BMI z-Scores from Different Growth References Are Not Comparable: An Example from a Weight Management Trial with an Anti-Obesity Medication in Pubertal Adolescents with Obesity.
- [Cardiovascular disease in diabetic patients: risk factors, clinical history and prevention].
- Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies.
- Influence of pH, Buffering Capacity, Ionic Strength, Bile Salts, and Model Drugs on Micellization Behaviour of Salcaprozate Sodium in Physiological Range pH Buffers.
- Physical Fitness with Exercise and GLP-1 Receptor Agonist Treatment Alone or Combined After Diet-Induced Weight Loss: A Secondary Analysis of a Randomized Controlled Trial in Adults with Obesity.
- The lack of efficacy of tirzepatide in mitigating cisplatin-induced neurotoxicity and cognitive impairment in rats.
- Effectiveness and safety of once-weekly subcutaneous semaglutide versus other glucose-lowering agents in real-world patients with type 2 diabetes: A retrospective, observational post-marketing study.
- The potential role of GLP-1 receptor agonists in substance use disorders - a systematic review.
- High Dose of Liraglutide Impairs Renal Function in Female Hypertensive Rats.
- Beyond Glycemic Control: Concurrent GLP-1 Receptor Agonist Use Is Associated with Reduced Urinary Adverse Events Following OnabotulinumtoxinA Treatment in Non-Diabetic Adults with Overactive Bladder.
- Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis.
- The impact of extended release exenatide as adjuvant therapy on hemoglobin A1C, weight, and total daily dose of insulin in patients with type 2 diabetes mellitus using U-500 insulin.
- Localized Semaglutide Injection for Hyperinsulinemia-Induced Lymphatic Dysfunction: A Narrative Review Proposing a Promising Metabolic Perspective for Lymphedema Therapy.
- Obesity medications in patients with recurrent weight gain or suboptimal clinical response following bariatric surgery: a meta-analysis.
- Evaluating semaglutide + LAI-287 (IcoSema) for the treatment of diabetes mellitus type II.
- A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial.
- Effect of switching from dulaglutide to tirzepatide on blood glucose and renal function.
- Semaglutide Hype or Hope: Evidence-based Review in Diabesity.
- Navigating compounded semaglutide: what health care providers need to know.
- Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
- Letter to the Editor: Intrahepatic Lipid Content After Insulin Glargine Addition to Metformin in Type II Diabetes Mellitus With Nonalcoholic Fatty Liver Disease.
- Semaglutide Associated With Less Insulin Need in Early Type 1 Diabetes.
- Glycemic control and weight changes in patients with type 2 diabetes intensified to three insulin regimens after therapeutic failure to exenatide.
- [Dyslipidemia and obesity 2011. Similarities and differences].
- Type 2 diabetes and cardiovascular disease: A metabolic overview of recent clinical trials.
- The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs.
- Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes.
- Early Adoption and Prescribing Patterns of Resmetirom: A Multi-Institutional National Analysis.
- GLP-1 Receptor Agonists and Psychiatric Outcomes in Adolescents: A Systematic Review and Meta-Analysis.
- Emulated Effects of Glucagon-Like Peptide 1 Receptor Agonist Therapy in the General Population.
- [Rare cause of insufficient metabolic control of diabetes mellitus - Case 10/2011].
- [An orally administered glucagon-like peptide 1 (GLP1) analogue: A landmark in the treatment of type 2 diabetes].
- Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology.
- Obesity Management in Youth with Duchenne Muscular Dystrophy: A Review of Metformin and Alternative Pharmacotherapies.
- Weight management treatment in obesity.
- A cost-controlling treatment strategy of adding liraglutide to insulin in type 2 diabetes.
- GLP-1 receptor agonists and GIP/GLP-1 co-agonists in the treatment of obesity in adolescents and the elderly.
- Comparison of trajectories of self-monitored glucose levels by hypoglycemia status over 52 weeks of treatment with insulin glargine or exenatide once weekly.
- The LEADER trial in type 2 diabetes: Were the characteristics and outcomes of the participants representative?
- Glucagon-like peptide-1 receptor agonists and obesity paradox in heart failure with preserved ejection fraction: a systematic review.
- The Influence of GLP-1 Agonists on Human Mesenchymal Stem Cells: A Systematic Review.
- Exposure-adjusted safety and efficacy of GLP-I and GLP-1/GIP receptor agonists compared with non-GLP-I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects.
- Dulaglutide for type 2 diabetes.
- National trends in prescription drug expenditures and projections for 2026.